Next Phase Newsletter

A venture capital firm headquartered in the US is currently investing from their 1st fund. The firm invests in Seed and Series A. The firm makes initial equity investments between $250K-$3M. The firm prefers to lead and requires a board seat; however, they can co-invest as well. The firm invests in the USA and will consider investments outside of the USA if a regulatory process has been completed. 
 
The firm invests in healthtech, medtech, and techbio. The firm has a particular consideration for IVD. For digital health (considered healthtech), the firm prefers software-based solutions, and has an overall investment focus on software-based solutions. For tech bio, the firm is interested in tech such as gene editing and cell therapies. For diagnostics and medical devices, the firm will only invest in class 1 and 510K and is not open to PMA. The firm requires companies to be revenue generating, indicating scale and likes to see annual repeat customers. 
 
The firm prefers to lead and requires a board seat. The firm is founder friendly and has no strict management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients has broad expertise in development sciences, delivery technologies, and multi-modality manufacturing. The firm is a preferred partner for personalized medicines, blockbuster drugs and consumer health brand extensions. The firm has launched a joint venture investment fund to invest strategically in early-stage startups and platforms. By investing in new technologies, partnering with innovators through co-development and in-licensing, across the academic and industry, the firm helps to bring disruptive innovation to the market. The firm invests globally but has primarily partnered with companies in North America and Europe to date. 
 
The firm invests in technology-enabled platform life sciences companies that are relevant to its science and technology and corporate innovation initiatives. Illustrative potential investments include next-generation biomanufacturing platforms, drug delivery platforms, drug-device combinations, cell-line engineering, mAb discovery, development tools, and inputs. The firm will consider investing in companies advancing therapeutic assets if they are also developing platforms technologies. 
 
The firm can lead or co-invest, and while it considers a board seat a plus, it is not a requirement after investing. The firm values the experience of serial entrepreneurs when partnering and focuses on strategic and deeper relationships. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporate venture arm of a pharmaceutical based in the US is looking to provide equity capital to seed and venture stage companies in the life science space, and invests across North America & Europe. The firm is looking to provide companies with $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year. 
 
The firm is currently looking for novel therapeutics, platform technologies, diagnostics, and vaccines. The firm is interested in novel drugs in broad disease areas including neuroscience (particularly neurodegeneration), immunology, inflammation, and rare disease, as well as diagnostics for neurodegenerative disorders. Current platform technology areas of interest include regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine. 
 
The firm strongly prefers that the company has a strong management team with experience in the industry. The firm historically has only invested as a co-investor although they are capable and looking to take a lead position if the correct opportunity arises. The firm is looking to allocate to companies that will eventually be able to partner long term with its parent company Mitsubishi Tanabe Pharma. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm based in the US is seeking to invest in Pre-Seed to Series A companies, with typical check sizes between $100K and $1M. The firm expects to make about 80% of their investments in North America, but has a global outlook and has evaluated opportunities from outside of North America. 
 
Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies. 
 
The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A group founded by medical device experts seeks to allocate 5-20 Million RMB (0.7-3 Million USD) in various early stage life science opportunities. The firm seeks to make several investments in the upcoming year and focusing on opportunities raising angel,  pre-A, Series A, and B rounds. The firm seeks to make use of their founders’ expertise and successes in the medical device industry to help guide their investments towards growth and success. The firm is investing out of a CNY fund and as a result, is currently focused on companies willing to start a joint venture in China. 
 
The firm is primarily interested in medical devices and in vitro diagnostic (IVD) technologies and/or companies. More specifically, they’re interested in opportunities in areas related to cardiology, neuromodulation, in vitro diagnostics, and imaging as that is where they have the most expertise. However, they are willing to look at other areas as well so long as the opportunity is interesting and has the potential to be developed. The firm is also interested in investing in R&D services as well. The firm’s most recent investment was in a company that utilized AI to process images in order for better and faster diagnoses. 
 
The firm heavily prefers that the company has a China angle to work with. They believe that they can contribute more to companies who wish to work in China through connections they have already made such as through helping acquire non-dilutive funds from the government of China and utilizing various connections in industrial parks across China. The firm also wishes to work with companies that are willing to work with the partners at the firm so that they can utilize their prior experiences to help the companies grow. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A multi-asset strategy single family office is involved in real estate management and venture investments. The group has offices in US and China, and the firm’s venture investment arm seeks to invest in early-stage, innovative technology companies. The firm typically engages in seed to series A rounds and prefers life science and healthcare companies with high-tech components. The initial check size from $100K-1M USD. The firm is interested in companies based in the US. 

The firm possesses extensive expertise in cross border investments and collaboration. The firm can leverage its local networks and resources if their portfolio companies have the willingness to expand their businesses in China on various fronts, such as securing additional funding. Because of this unique strategic advantage, the firm maintains a special interest in companies with a China angle and firms with products or technologies suited for the Chinese market. 

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment. 
 
The firm seeks life science and healthcare companies that incorporate high-tech components, such as AI in healthcare and life sciences. The firm is open to considering medical devices, and digital health, and its opportunistic regarding subsectors and indications. Due to the scientific background of its team, the firm is particularly interested in chronic diseases such as diabetes and cardiovascular diseases. 
 
There are no specific requirements for the company and the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A USA-based venture capital firm focuses on biotech investments with particular interest in the following indications: oncology, immunology, CNS/neurology, among others. The firm also invests in rare and orphan diseases. The firm is generally stage agnostic, and can invest in anywhere from pre-clinical to pre-launch, commercial stage companies. The firm is capable of investing up to $15M over the life of the company, and is open to acting as either the lead/co-lead or co-investor. 
 
The firm focuses on investments in therapeutics companies across all stages of development, from pre-clinical, clinical, to commercial stage. The firm is most interested in indications of high unmet medical need, including oncology, immunology, neurology, and rare diseases and may seek assets in other indications on a case-by-case basis. 
 
The firm seeks to work with companies backed by a experienced management team with strong scientific expertise. The firm invests in both public and private companies, and is open to acting as either the lead/co-lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.